54. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL and Russell 
DW. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in 
its mRNA. Cell, Nov 1984;39(1):27-38. 
55. Davis CG, van Driel IR, Russell DW, Brown MS and Goldstein JL. The low density 
lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for 
rapid endocytosis. J Biol Chem, Mar 25 1987;262(9):4075-82. 
56. Hofmann SL, Russell DW, Brown MS, Goldstein JL and Hammer RE. Overexpression of 
low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. 
Science, Mar 11, 1 988 ;239(4845) :1 277-81 . 
57. Yokode M, Hammer RE, Ishibashi S., Brown MS and Goldstein JL. Diet-induced 
hypercholesterolemia in mice: prevention by overexpression of LDL receptors. 
Science, Nov 30 1990;250(4985):1 273-75. 
58. Khachadurian AK. Cholestyramine therapy in patients homozygous for familial 
hypercholesterolemia (familial hypercholesterolemic xanthomatosis). J Atheroscler 
Res, Jan-Feb 1 968;8(1 ):1 77-88. 
59. Levy Rl, Fredrickson DS, Stone NJ, Bilheimer DW, Brown WV, Glueck CJ, Gotto AM, 
Herbert PN, Kwiterovich PO, Langer T, LaTosa J, Lux SE, Rider AK, Shulman RS and 
Sloan HR. Cholestyramine in type II hyperlipoproteinemia. A double-blind trial. Ann 
Intern Med, Jul 1973;79(1):51-8. 
60. Yamamoto A, Yamamura T, Yokoyama S, Sudo H and Matsuzawa Y. Combined drug 
therapy-cholstyramine and compactin-for familial hypercholesterolemia. Int J Clin 
Pharmacol Ther Toxicol, Sep 1984;22(9):493-7. 
61 . Malloy MJ, Kane JP, Kunitake ST and Tun P. Complementarity of colestipol, niacin, and 
lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med, Nov 
1 987;1 0 7 ( 5 ) : 6 1 6-23. 
62. Uauy R, Vega GL, Grundy SM and Bilheimer DM. Lovastatin therapy in receptor- 
negative homozygous familial hypercholesterolemia: lack of effect on low-density 
lipoprotein concentrations or turnover. J Pediatr, Aug 1988;1 13(2):387-92. 
63. Stein Ea. Treatment of familial hypercholesterolemia with drugs in children. 
Arteriosclerosis, Jan-Feb 1989;9(1 Suppl) :I1 45-51 . 
64. Starzl TE, Putnam CW, Chase HP and Porter KA. Portacaval shunt in 
hyperlipoproteinaemia. Lancet, Oct 27 1973;2(835):940-44. 
65. Starzl TE, Chase HP, Ahrens EH Jr, McNamara DJ, Bilheimer DW, Schaefer EJ, Rey J, 
Porter KA, Stein E, Francavilla A and Benson LN. Portacaval shunt in patients with 
familial hypercholesterolemia. Ann Surg, Sep 1983;198(3):273-83. 
66. Thompson GR, Lowenthal R and Myant NB. Plasma exchange in the management of 
homozygous familial hypercholesterolemia. Lancet, May 31 1975;1 (791 8):1 208-11. 
67. Apstein CS, Zilversmit DB, Lees RS and George PK. Effect of intensive plasmapheresis 
on the plasma cholesterol concentration with familial hypercholesterolemia. 
Atherosclerosis, Oct 1978;31 (2):1 05-15. 
68. King ME, Breslow JL and Lees RS. Plasma-exchange therapy of homozygous familial 
hypercholesterolemia. N Engl J Med, Jun 1980;302(26):1 457-9. 
69. Myant NB. Regression of coronary atherosclerosis in man. Adv Exp Med Biol, 
1984;168:139-52. 
70. Yokoyama S, Hayashi R, Satani M and Yamamoto A. Selective removal of low density 
lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis, 
Nov-Dec 1 985;5(6):61 3-22. 
71. Postiglione A and Thompson GR. Experience with plasma-exchange in homozygous 
familial hypercholesterolemia. Prog Clin Biol Res, 1985;188:213-20. 
72. Thompson GR, Miller JP and Breslow JL. Improved survival of patients with 
homozygous familial hypercholesterolemia treated with plasma exchange. Br Med J 
[Clin Res], Dec 14, 1 985;291 (651 0):1 671-3. 
Recombinant DNA Research, Volume 15 
[199] 
